Skip to search formSkip to main contentSkip to account menu

HIVAC-1e

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

AIDS Vaccines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
1999
Review
1999
Technology evaluation: HIVAC-1e.
  • R. Zheng
  • Current opinion in molecular therapeutics (Print)
  • 1999
  • Corpus ID: 33030077
Bristol-Myers Squibb is developing a vaccine, HIVAC-1e, comprised of a recombinant vaccinia virus expressing the HIV-1 gp160… 
1995
1995
A vaccinia-gp160-based vaccine but not a gp160 protein vaccine elicits anti-gp160 cytotoxic T lymphocytes in some HIV-1 seronegative vaccinees.
Cytotoxic T lymphocytes (CTL) play an important role in the immune response to viral infection by recognizing and destroying… 
1994
1994
Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus. The National Institute of Allergy and Infectious Diseases…
Priming with a live recombinant vector followed by subunit boosting is a promising strategy for human immunodeficiency virus (HIV… 
Highly Cited
1993
Highly Cited
1993
V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding…
Sera from 11 volunteers immunized with a recombinant HIV-1 gp160-expressing vaccinia virus (HIVAC-1e; Oncogen/Bristol-Myers… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)